 | Up a level |
Gadea, O. Saavedra Santa, Greil, R., De Jonge, M. J. A., Tan, D., Jerusalem, G., Damian, S., Grell, P., Wainberg, Z., Wolf, J., Joerger, M., Carlino, M. S., Kasper, S., Yap, T. A., Otero, J., Yang, X., Nesbitt, V., Kim, J., Lee, L. Ho, Choudhury, S. and Leal, T. A. (2021). Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC). Ann. Oncol., 32. S. S552 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852